Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study
Objective Early‐onset obsessive–compulsive disorder (EOCD) and late‐onset obsessive–compulsive disorder (LOCD) are distinct subtypes of obsessive–compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability be...
Gespeichert in:
| Veröffentlicht in: | Human psychopharmacology 2018-01, Vol.33 (1), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | |
| container_title | Human psychopharmacology |
| container_volume | 33 |
| creator | Lee, Junhee Kim, Bo‐Hyung Kim, Euitae Howes, Oliver D. Cho, Kang Ik Kevin Yoon, Youngwoo Bryan Kwon, Jun Soo |
| description | Objective
Early‐onset obsessive–compulsive disorder (EOCD) and late‐onset obsessive–compulsive disorder (LOCD) are distinct subtypes of obsessive–compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability between medicated EOCD and LOCD is unexplored yet.
Methods
Six EOCD and 6 LOCD patients were enrolled. They underwent serial [11C]DASB positron emission tomography scans during maintenance therapy with escitalopram, and their plasma concentration of escitalopram was measured simultaneously with the scan. Then, the drug‐free binding potential of SERT was calculated by pharmacokinetic–pharmacodynamic modelling.
Results
In comparison with LOCD patients, SERT availability was significantly higher in the putamen of EOCD patients (U = 4, p = .026), but not in the caudate nucleus (U = 14, p = .589), thalamus (U = 16, p = .818), and dorsal raphe nucleus (U = 7, p = .093). Binding potential of putamen showed a negative correlation (r = −.580, p = .048) with age of onset of the disease, but not with the Yale–Brown Obsessive Compulsive Scale scores.
Conclusions
These findings indicate that the earlier the age of onset of OCD, the less serotonergic pathology there is and that this difference remains even after long‐term serotonin reuptake inhibitor treatment. Clinically, it might suggest that nonserotonergic treatments would be a better option for EOCD patients. |
| doi_str_mv | 10.1002/hup.2642 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1991052241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1991052241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3832-82b9f70b7adcf3e9827fb31a3257f2edc7e529736e40753083ac225d2dc8cc963</originalsourceid><addsrcrecordid>eNp1kcFq3DAQhkVISbZpIE8QBLn04lQarVdWb9tt2i0EGmhyKsHI8nijYFuuJKf4lkco9Nqny5NU201762mYmW_-H-Yn5ISzc84YvLkbh3NYzGGPzDhTKuNMyn0yY0WRZwsAOCQvQ7hnLO2YOiCHoICzBM3Ir7Xd3KGnAb2Lrrc9jV73YXA-pql-0LbVlW1tnGjaofbt9PT4w_UBI3VVwBDsAz49_jSuG8Z229DaBufrdD3oaLGPgY59ajfO9huKwdioWzd43SUr1LFLyFu6pF85X92-X355R68urmmIYz29Ii8a3QY8fq5H5ObDxfVqnV1-_vhptbzMjCgEZAVUqpGskro2jUBVgGwqwbWAXDaAtZGYg5JigXMmc8EKoQ1AXkNtCmPUQhyRs53u4N23EUMs793o-2RZcqU4ywHmPFGvd5TxLgSPTTl422k_lZyV2xjKFEO5jSGhp8-CY9Vh_Q_8-_cEZDvgu21x-q9Qub65-iP4G_ICllM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1991052241</pqid></control><display><type>article</type><title>Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Lee, Junhee ; Kim, Bo‐Hyung ; Kim, Euitae ; Howes, Oliver D. ; Cho, Kang Ik Kevin ; Yoon, Youngwoo Bryan ; Kwon, Jun Soo</creator><creatorcontrib>Lee, Junhee ; Kim, Bo‐Hyung ; Kim, Euitae ; Howes, Oliver D. ; Cho, Kang Ik Kevin ; Yoon, Youngwoo Bryan ; Kwon, Jun Soo</creatorcontrib><description>Objective
Early‐onset obsessive–compulsive disorder (EOCD) and late‐onset obsessive–compulsive disorder (LOCD) are distinct subtypes of obsessive–compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability between medicated EOCD and LOCD is unexplored yet.
Methods
Six EOCD and 6 LOCD patients were enrolled. They underwent serial [11C]DASB positron emission tomography scans during maintenance therapy with escitalopram, and their plasma concentration of escitalopram was measured simultaneously with the scan. Then, the drug‐free binding potential of SERT was calculated by pharmacokinetic–pharmacodynamic modelling.
Results
In comparison with LOCD patients, SERT availability was significantly higher in the putamen of EOCD patients (U = 4, p = .026), but not in the caudate nucleus (U = 14, p = .589), thalamus (U = 16, p = .818), and dorsal raphe nucleus (U = 7, p = .093). Binding potential of putamen showed a negative correlation (r = −.580, p = .048) with age of onset of the disease, but not with the Yale–Brown Obsessive Compulsive Scale scores.
Conclusions
These findings indicate that the earlier the age of onset of OCD, the less serotonergic pathology there is and that this difference remains even after long‐term serotonin reuptake inhibitor treatment. Clinically, it might suggest that nonserotonergic treatments would be a better option for EOCD patients.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.2642</identifier><identifier>PMID: 29210107</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>[11C]DASB PET ; Adult ; Age ; Age of Onset ; Antidepressants ; Availability ; Benzylamines ; Brain - diagnostic imaging ; Brain - drug effects ; Brain - metabolism ; Brain Mapping ; Carbon Radioisotopes ; Case-Control Studies ; Caudate nucleus ; Citalopram ; Citalopram - pharmacokinetics ; Citalopram - therapeutic use ; Dorsal raphe nucleus ; escitalopram ; Humans ; Male ; Models, Biological ; Neuroses ; Obsessive compulsive disorder ; Obsessive-Compulsive Disorder - diagnostic imaging ; Obsessive-Compulsive Disorder - drug therapy ; Obsessive-Compulsive Disorder - metabolism ; Patients ; Pharmacodynamics ; Positron emission tomography ; Psychiatric Status Rating Scales ; Putamen ; Radiopharmaceuticals ; Raphe nuclei ; Serotonin ; Serotonin Plasma Membrane Transport Proteins - metabolism ; Serotonin transporter ; Serotonin uptake inhibitors ; Serotonin Uptake Inhibitors - pharmacokinetics ; Serotonin Uptake Inhibitors - therapeutic use ; Thalamus</subject><ispartof>Human psychopharmacology, 2018-01, Vol.33 (1), p.n/a</ispartof><rights>Copyright © 2017 John Wiley & Sons, Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3832-82b9f70b7adcf3e9827fb31a3257f2edc7e529736e40753083ac225d2dc8cc963</citedby><cites>FETCH-LOGICAL-c3832-82b9f70b7adcf3e9827fb31a3257f2edc7e529736e40753083ac225d2dc8cc963</cites><orcidid>0000-0003-4327-1911</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhup.2642$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhup.2642$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29210107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Junhee</creatorcontrib><creatorcontrib>Kim, Bo‐Hyung</creatorcontrib><creatorcontrib>Kim, Euitae</creatorcontrib><creatorcontrib>Howes, Oliver D.</creatorcontrib><creatorcontrib>Cho, Kang Ik Kevin</creatorcontrib><creatorcontrib>Yoon, Youngwoo Bryan</creatorcontrib><creatorcontrib>Kwon, Jun Soo</creatorcontrib><title>Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study</title><title>Human psychopharmacology</title><addtitle>Hum Psychopharmacol</addtitle><description>Objective
Early‐onset obsessive–compulsive disorder (EOCD) and late‐onset obsessive–compulsive disorder (LOCD) are distinct subtypes of obsessive–compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability between medicated EOCD and LOCD is unexplored yet.
Methods
Six EOCD and 6 LOCD patients were enrolled. They underwent serial [11C]DASB positron emission tomography scans during maintenance therapy with escitalopram, and their plasma concentration of escitalopram was measured simultaneously with the scan. Then, the drug‐free binding potential of SERT was calculated by pharmacokinetic–pharmacodynamic modelling.
Results
In comparison with LOCD patients, SERT availability was significantly higher in the putamen of EOCD patients (U = 4, p = .026), but not in the caudate nucleus (U = 14, p = .589), thalamus (U = 16, p = .818), and dorsal raphe nucleus (U = 7, p = .093). Binding potential of putamen showed a negative correlation (r = −.580, p = .048) with age of onset of the disease, but not with the Yale–Brown Obsessive Compulsive Scale scores.
Conclusions
These findings indicate that the earlier the age of onset of OCD, the less serotonergic pathology there is and that this difference remains even after long‐term serotonin reuptake inhibitor treatment. Clinically, it might suggest that nonserotonergic treatments would be a better option for EOCD patients.</description><subject>[11C]DASB PET</subject><subject>Adult</subject><subject>Age</subject><subject>Age of Onset</subject><subject>Antidepressants</subject><subject>Availability</subject><subject>Benzylamines</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain Mapping</subject><subject>Carbon Radioisotopes</subject><subject>Case-Control Studies</subject><subject>Caudate nucleus</subject><subject>Citalopram</subject><subject>Citalopram - pharmacokinetics</subject><subject>Citalopram - therapeutic use</subject><subject>Dorsal raphe nucleus</subject><subject>escitalopram</subject><subject>Humans</subject><subject>Male</subject><subject>Models, Biological</subject><subject>Neuroses</subject><subject>Obsessive compulsive disorder</subject><subject>Obsessive-Compulsive Disorder - diagnostic imaging</subject><subject>Obsessive-Compulsive Disorder - drug therapy</subject><subject>Obsessive-Compulsive Disorder - metabolism</subject><subject>Patients</subject><subject>Pharmacodynamics</subject><subject>Positron emission tomography</subject><subject>Psychiatric Status Rating Scales</subject><subject>Putamen</subject><subject>Radiopharmaceuticals</subject><subject>Raphe nuclei</subject><subject>Serotonin</subject><subject>Serotonin Plasma Membrane Transport Proteins - metabolism</subject><subject>Serotonin transporter</subject><subject>Serotonin uptake inhibitors</subject><subject>Serotonin Uptake Inhibitors - pharmacokinetics</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Thalamus</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFq3DAQhkVISbZpIE8QBLn04lQarVdWb9tt2i0EGmhyKsHI8nijYFuuJKf4lkco9Nqny5NU201762mYmW_-H-Yn5ISzc84YvLkbh3NYzGGPzDhTKuNMyn0yY0WRZwsAOCQvQ7hnLO2YOiCHoICzBM3Ir7Xd3KGnAb2Lrrc9jV73YXA-pql-0LbVlW1tnGjaofbt9PT4w_UBI3VVwBDsAz49_jSuG8Z229DaBufrdD3oaLGPgY59ajfO9huKwdioWzd43SUr1LFLyFu6pF85X92-X355R68urmmIYz29Ii8a3QY8fq5H5ObDxfVqnV1-_vhptbzMjCgEZAVUqpGskro2jUBVgGwqwbWAXDaAtZGYg5JigXMmc8EKoQ1AXkNtCmPUQhyRs53u4N23EUMs793o-2RZcqU4ywHmPFGvd5TxLgSPTTl422k_lZyV2xjKFEO5jSGhp8-CY9Vh_Q_8-_cEZDvgu21x-q9Qub65-iP4G_ICllM</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Lee, Junhee</creator><creator>Kim, Bo‐Hyung</creator><creator>Kim, Euitae</creator><creator>Howes, Oliver D.</creator><creator>Cho, Kang Ik Kevin</creator><creator>Yoon, Youngwoo Bryan</creator><creator>Kwon, Jun Soo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0003-4327-1911</orcidid></search><sort><creationdate>201801</creationdate><title>Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study</title><author>Lee, Junhee ; Kim, Bo‐Hyung ; Kim, Euitae ; Howes, Oliver D. ; Cho, Kang Ik Kevin ; Yoon, Youngwoo Bryan ; Kwon, Jun Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3832-82b9f70b7adcf3e9827fb31a3257f2edc7e529736e40753083ac225d2dc8cc963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>[11C]DASB PET</topic><topic>Adult</topic><topic>Age</topic><topic>Age of Onset</topic><topic>Antidepressants</topic><topic>Availability</topic><topic>Benzylamines</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain Mapping</topic><topic>Carbon Radioisotopes</topic><topic>Case-Control Studies</topic><topic>Caudate nucleus</topic><topic>Citalopram</topic><topic>Citalopram - pharmacokinetics</topic><topic>Citalopram - therapeutic use</topic><topic>Dorsal raphe nucleus</topic><topic>escitalopram</topic><topic>Humans</topic><topic>Male</topic><topic>Models, Biological</topic><topic>Neuroses</topic><topic>Obsessive compulsive disorder</topic><topic>Obsessive-Compulsive Disorder - diagnostic imaging</topic><topic>Obsessive-Compulsive Disorder - drug therapy</topic><topic>Obsessive-Compulsive Disorder - metabolism</topic><topic>Patients</topic><topic>Pharmacodynamics</topic><topic>Positron emission tomography</topic><topic>Psychiatric Status Rating Scales</topic><topic>Putamen</topic><topic>Radiopharmaceuticals</topic><topic>Raphe nuclei</topic><topic>Serotonin</topic><topic>Serotonin Plasma Membrane Transport Proteins - metabolism</topic><topic>Serotonin transporter</topic><topic>Serotonin uptake inhibitors</topic><topic>Serotonin Uptake Inhibitors - pharmacokinetics</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Thalamus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Junhee</creatorcontrib><creatorcontrib>Kim, Bo‐Hyung</creatorcontrib><creatorcontrib>Kim, Euitae</creatorcontrib><creatorcontrib>Howes, Oliver D.</creatorcontrib><creatorcontrib>Cho, Kang Ik Kevin</creatorcontrib><creatorcontrib>Yoon, Youngwoo Bryan</creatorcontrib><creatorcontrib>Kwon, Jun Soo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Junhee</au><au>Kim, Bo‐Hyung</au><au>Kim, Euitae</au><au>Howes, Oliver D.</au><au>Cho, Kang Ik Kevin</au><au>Yoon, Youngwoo Bryan</au><au>Kwon, Jun Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum Psychopharmacol</addtitle><date>2018-01</date><risdate>2018</risdate><volume>33</volume><issue>1</issue><epage>n/a</epage><issn>0885-6222</issn><eissn>1099-1077</eissn><abstract>Objective
Early‐onset obsessive–compulsive disorder (EOCD) and late‐onset obsessive–compulsive disorder (LOCD) are distinct subtypes of obsessive–compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability between medicated EOCD and LOCD is unexplored yet.
Methods
Six EOCD and 6 LOCD patients were enrolled. They underwent serial [11C]DASB positron emission tomography scans during maintenance therapy with escitalopram, and their plasma concentration of escitalopram was measured simultaneously with the scan. Then, the drug‐free binding potential of SERT was calculated by pharmacokinetic–pharmacodynamic modelling.
Results
In comparison with LOCD patients, SERT availability was significantly higher in the putamen of EOCD patients (U = 4, p = .026), but not in the caudate nucleus (U = 14, p = .589), thalamus (U = 16, p = .818), and dorsal raphe nucleus (U = 7, p = .093). Binding potential of putamen showed a negative correlation (r = −.580, p = .048) with age of onset of the disease, but not with the Yale–Brown Obsessive Compulsive Scale scores.
Conclusions
These findings indicate that the earlier the age of onset of OCD, the less serotonergic pathology there is and that this difference remains even after long‐term serotonin reuptake inhibitor treatment. Clinically, it might suggest that nonserotonergic treatments would be a better option for EOCD patients.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29210107</pmid><doi>10.1002/hup.2642</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4327-1911</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-6222 |
| ispartof | Human psychopharmacology, 2018-01, Vol.33 (1), p.n/a |
| issn | 0885-6222 1099-1077 |
| language | eng |
| recordid | cdi_proquest_journals_1991052241 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | [11C]DASB PET Adult Age Age of Onset Antidepressants Availability Benzylamines Brain - diagnostic imaging Brain - drug effects Brain - metabolism Brain Mapping Carbon Radioisotopes Case-Control Studies Caudate nucleus Citalopram Citalopram - pharmacokinetics Citalopram - therapeutic use Dorsal raphe nucleus escitalopram Humans Male Models, Biological Neuroses Obsessive compulsive disorder Obsessive-Compulsive Disorder - diagnostic imaging Obsessive-Compulsive Disorder - drug therapy Obsessive-Compulsive Disorder - metabolism Patients Pharmacodynamics Positron emission tomography Psychiatric Status Rating Scales Putamen Radiopharmaceuticals Raphe nuclei Serotonin Serotonin Plasma Membrane Transport Proteins - metabolism Serotonin transporter Serotonin uptake inhibitors Serotonin Uptake Inhibitors - pharmacokinetics Serotonin Uptake Inhibitors - therapeutic use Thalamus |
| title | Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [11C]DASB PET study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A55%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20serotonin%20transporter%20availability%20in%20early%E2%80%90onset%20obsessive%E2%80%93compulsive%20disorder%20patients%20undergoing%20escitalopram%20treatment:%20A%20%5B11C%5DDASB%20PET%20study&rft.jtitle=Human%20psychopharmacology&rft.au=Lee,%20Junhee&rft.date=2018-01&rft.volume=33&rft.issue=1&rft.epage=n/a&rft.issn=0885-6222&rft.eissn=1099-1077&rft_id=info:doi/10.1002/hup.2642&rft_dat=%3Cproquest_cross%3E1991052241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1991052241&rft_id=info:pmid/29210107&rfr_iscdi=true |